首页 > 最新文献

Endocrine最新文献

英文 中文
A machine learning-based diagnosis modeling of IgG4 Hashimoto's thyroiditis. 基于机器学习的 IgG4 桥本氏甲状腺炎诊断模型。
IF 3.7 3区 医学 Q2 Medicine Pub Date : 2024-11-01 Epub Date: 2024-05-29 DOI: 10.1007/s12020-024-03889-y
Chenxu Zhao, Zhiming Sun, Yang Yu, Yiwei Lou, Liyuan Liu, Ge Li, Jumei Liu, Lei Chen, Sainan Zhu, Yu Huang, Yang Zhang, Ying Gao

Purpose: This study aims to develop a non-invasive diagnosis model using machine learning (ML) for identifying high-risk IgG4 Hashimoto's thyroiditis (HT) patients.

Methods: A retrospective cohort of 93 HT patients and a prospective cohort of 179 HT patients were collected. According to the immunohistochemical and pathological results, the patients were divided into IgG4 HT group and non-IgG4 HT group. Serum TgAb IgG4 and TPOAb IgG4 were detected by ELISAs. A logistic regression model, support vector machine (SVM) and random forest (RF) were used to establish a clinical diagnosis model for IgG4 HT.

Results: Among these 272 patients, 40 (14.7%) were diagnosed with IgG4 HT. Patients with IgG4 HT were younger than those with non-IgG4 HT (P < 0.05). Serum levels of TgAb IgG4 and TPOAb IgG4 in IgG4 HT group were significantly higher than those in non-IgG4 HT group (P < 0.05). There were no significant differences in gender, disease duration, goiter, preoperative thyroid function status, preoperative TgAb or TPOAb levels, and thyroid ultrasound characteristics between the two groups (all P > 0.05). The accuracy, sensitivity, and specificity were 57%, 78%, and 79% for logistic regression model of IgG4 HT, 80 ± 7%, 84.7% ± 2.6%, and 75.4% ± 9.6% for the RF model and 78 ± 5%, 89.8% ± 5.7%, and 64.7% ± 5.7% for the SVM model. The RF model works better than SVM. The area under the ROC curve of RF ranged 0.87 to 0.92.

Conclusion: A clinical diagnosis model for IgG4 HT established by RF model might help the early recognition of the high-risk patients of IgG4 HT.

目的:本研究旨在利用机器学习(ML)开发一种无创诊断模型,用于识别高风险 IgG4 桥本氏甲状腺炎(HT)患者:收集了93名桥本氏甲状腺炎患者的回顾性队列和179名桥本氏甲状腺炎患者的前瞻性队列。根据免疫组化和病理结果,将患者分为 IgG4 HT 组和非 IgG4 HT 组。通过 ELISA 检测血清 TgAb IgG4 和 TPOAb IgG4。采用逻辑回归模型、支持向量机(SVM)和随机森林(RF)建立了 IgG4 HT 的临床诊断模型:结果:在 272 名患者中,有 40 人(14.7%)被确诊为 IgG4 HT。IgG4 HT患者比非IgG4 HT患者更年轻(P 0.05)。IgG4 HT 的逻辑回归模型的准确性、灵敏度和特异性分别为 57%、78% 和 79%,RF 模型的准确性、灵敏度和特异性分别为 80 ± 7%、84.7% ± 2.6% 和 75.4% ± 9.6%,SVM 模型的准确性、灵敏度和特异性分别为 78 ± 5%、89.8% ± 5.7% 和 64.7% ± 5.7%。RF 模型的效果优于 SVM。RF 的 ROC 曲线下面积为 0.87 至 0.92:通过 RF 模型建立的 IgG4 HT 临床诊断模型可能有助于早期识别 IgG4 HT 高危患者。
{"title":"A machine learning-based diagnosis modeling of IgG4 Hashimoto's thyroiditis.","authors":"Chenxu Zhao, Zhiming Sun, Yang Yu, Yiwei Lou, Liyuan Liu, Ge Li, Jumei Liu, Lei Chen, Sainan Zhu, Yu Huang, Yang Zhang, Ying Gao","doi":"10.1007/s12020-024-03889-y","DOIUrl":"10.1007/s12020-024-03889-y","url":null,"abstract":"<p><strong>Purpose: </strong>This study aims to develop a non-invasive diagnosis model using machine learning (ML) for identifying high-risk IgG4 Hashimoto's thyroiditis (HT) patients.</p><p><strong>Methods: </strong>A retrospective cohort of 93 HT patients and a prospective cohort of 179 HT patients were collected. According to the immunohistochemical and pathological results, the patients were divided into IgG4 HT group and non-IgG4 HT group. Serum TgAb IgG4 and TPOAb IgG4 were detected by ELISAs. A logistic regression model, support vector machine (SVM) and random forest (RF) were used to establish a clinical diagnosis model for IgG4 HT.</p><p><strong>Results: </strong>Among these 272 patients, 40 (14.7%) were diagnosed with IgG4 HT. Patients with IgG4 HT were younger than those with non-IgG4 HT (P < 0.05). Serum levels of TgAb IgG4 and TPOAb IgG4 in IgG4 HT group were significantly higher than those in non-IgG4 HT group (P < 0.05). There were no significant differences in gender, disease duration, goiter, preoperative thyroid function status, preoperative TgAb or TPOAb levels, and thyroid ultrasound characteristics between the two groups (all P > 0.05). The accuracy, sensitivity, and specificity were 57%, 78%, and 79% for logistic regression model of IgG4 HT, 80 ± 7%, 84.7% ± 2.6%, and 75.4% ± 9.6% for the RF model and 78 ± 5%, 89.8% ± 5.7%, and 64.7% ± 5.7% for the SVM model. The RF model works better than SVM. The area under the ROC curve of RF ranged 0.87 to 0.92.</p><p><strong>Conclusion: </strong>A clinical diagnosis model for IgG4 HT established by RF model might help the early recognition of the high-risk patients of IgG4 HT.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"672-681"},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141161506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Acquired thyroid-stimulating hormone, luteinizing hormone, and follicle-stimulating hormone deficiencies with circulating anti-glycoprotein hormones alpha chain-positive cell antibodies. 后天性促甲状腺激素、促黄体生成素和促卵泡激素缺乏症伴有循环抗糖蛋白激素α链阳性细胞抗体。
IF 3.7 3区 医学 Q2 Medicine Pub Date : 2024-11-01 Epub Date: 2024-06-21 DOI: 10.1007/s12020-024-03922-0
Hironori Bando, Masaaki Yamamoto, Genzo Iguchi, Wataru Ogawa

Background: A patient with systemic lupus erythematosus (SLE) suffered from acquired thyroid-stimulating hormone (TSH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) deficiencies. MRI findings revealed a slight atrophy of the pituitary gland. Further, the serum concentration of the covalent alpha subunit (glycoprotein hormones alpha chain [CGA]) in TSH-, LH-, and FSH-positive cells was below the detectable range. Because SLE is an autoimmune disorder, autoimmunity against the pituitary gland was suspected as the cause of pituitary deficiency.

Methods and results: Immunofluorescence analysis showed that the patient's immunoglobulin G recognized CGA-positive cells in the pituitary gland; therefore, autoimmunity against CGA-positive cells may have caused TSH, LH, and FSH deficiencies in this patient. Moreover, cell-specific autoimmunity impairs pituitary hormone levels. Further research is required to clarify whether acquired TSH, LH, and FSH deficiencies are common in patients with SLE or other autoimmune diseases.

Conclusion: Our findings highlight a unique case of acquired TSH, LH, and FSH deficiencies caused by circulating anti-CGA-positive cell antibodies, introducing a novel clinical concept of acquired hypopituitarism.

背景:一名系统性红斑狼疮(SLE)患者患有后天性促甲状腺激素(TSH)、促黄体生成素(LH)和促卵泡激素(FSH)缺乏症。核磁共振成像结果显示垂体轻微萎缩。此外,TSH、LH和FSH阳性细胞中共价α亚基(糖蛋白激素α链[CGA])的血清浓度低于可检测范围。由于系统性红斑狼疮是一种自身免疫性疾病,因此怀疑垂体自身免疫是导致垂体功能不足的原因:免疫荧光分析显示,患者的免疫球蛋白G能识别垂体中的CGA阳性细胞;因此,针对CGA阳性细胞的自身免疫可能是导致该患者TSH、LH和FSH缺乏的原因。此外,细胞特异性自身免疫也会损害垂体激素水平。要弄清获得性 TSH、LH 和 FSH 缺乏是否常见于系统性红斑狼疮或其他自身免疫性疾病患者,还需要进一步研究:我们的研究结果突显了一个由循环抗CGA阳性细胞抗体引起的获得性TSH、LH和FSH缺乏症的独特病例,引入了获得性垂体功能减退症的新临床概念。
{"title":"Acquired thyroid-stimulating hormone, luteinizing hormone, and follicle-stimulating hormone deficiencies with circulating anti-glycoprotein hormones alpha chain-positive cell antibodies.","authors":"Hironori Bando, Masaaki Yamamoto, Genzo Iguchi, Wataru Ogawa","doi":"10.1007/s12020-024-03922-0","DOIUrl":"10.1007/s12020-024-03922-0","url":null,"abstract":"<p><strong>Background: </strong>A patient with systemic lupus erythematosus (SLE) suffered from acquired thyroid-stimulating hormone (TSH), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) deficiencies. MRI findings revealed a slight atrophy of the pituitary gland. Further, the serum concentration of the covalent alpha subunit (glycoprotein hormones alpha chain [CGA]) in TSH-, LH-, and FSH-positive cells was below the detectable range. Because SLE is an autoimmune disorder, autoimmunity against the pituitary gland was suspected as the cause of pituitary deficiency.</p><p><strong>Methods and results: </strong>Immunofluorescence analysis showed that the patient's immunoglobulin G recognized CGA-positive cells in the pituitary gland; therefore, autoimmunity against CGA-positive cells may have caused TSH, LH, and FSH deficiencies in this patient. Moreover, cell-specific autoimmunity impairs pituitary hormone levels. Further research is required to clarify whether acquired TSH, LH, and FSH deficiencies are common in patients with SLE or other autoimmune diseases.</p><p><strong>Conclusion: </strong>Our findings highlight a unique case of acquired TSH, LH, and FSH deficiencies caused by circulating anti-CGA-positive cell antibodies, introducing a novel clinical concept of acquired hypopituitarism.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"769-773"},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141436711","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study. 更正:甲状腺全切除术后分化型甲状腺癌患者接受 131I 治疗的长期疗效:一项回顾性研究》(Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy)。
IF 3.7 3区 医学 Q2 Medicine Pub Date : 2024-11-01 DOI: 10.1007/s12020-024-03923-z
Xue Yin, Chao Lu, Danyang Sun, Yanhui Ji, Yan Wang, Hongyuan Zheng, Ziyu Ma, Qiang Jia, Jian Tan, Wei Zheng
{"title":"Correction to: Stimulating thyroglobulin to TSH ratio predict long-term efficacy of <sup>131</sup>I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study.","authors":"Xue Yin, Chao Lu, Danyang Sun, Yanhui Ji, Yan Wang, Hongyuan Zheng, Ziyu Ma, Qiang Jia, Jian Tan, Wei Zheng","doi":"10.1007/s12020-024-03923-z","DOIUrl":"10.1007/s12020-024-03923-z","url":null,"abstract":"","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"863"},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Thyrotropin (TSH) and thyroid autoimmunity are predictive factors for the incidental discovery of papillary thyroid microcarcinoma during thyroidectomy. 促甲状腺激素(TSH)和甲状腺自身免疫是甲状腺切除术中偶然发现甲状腺乳头状微癌的预测因素。
IF 3.7 3区 医学 Q2 Medicine Pub Date : 2024-11-01 Epub Date: 2024-06-19 DOI: 10.1007/s12020-024-03907-z
Aglaia Kyrilli, Rafaella Schoinochoriti, Valerie Chatzopoulos, Nabila Bahar, Jason Bouziotis, Nicky D'Haene, Isabelle Salmon, Maria Ruiz, Bernard Corvilain

Purpose: To identify clinical, biological and pathological risk factors for the incidental discovery of papillary thyroid microcarcinomas (PTMCs) in patients undergoing thyroidectomy for presumed benign conditions.

Methods: Cross sectional, single center study, involving all consecutive patients (N = 3015) who were submitted to thyroid surgery between 2001-2019. All medical files were retrospectively reviewed. A total of 1961 patients in the benign group and 145 patients in PTMC group were analyzed.

Results: No significant differences in age, sex, body mass index, smoking status, thyroid volume or weight and preoperative thyroxine treatment between benign and PTMC groups were observed. Circulating anti- thyroid antibodies, histological thyroiditis and serum thyrotropin (TSH) were significantly associated with PTMC in univariable analysis. Independent risk factors for incidental PTMC by multivariable analysis where possible (OR: 1.51, 95% CI: 0.99-2.28) and certain (OR: 1.74, 95% CI: 1.09-2.78) thyroid autoimmunity (p = 0.002) and higher serum TSH (OR: 1.25, 95% CI: 1.08-1.45, p = 0.03), whereas thyroid lobectomy was associated with a lower risk of PTMC (OR: 0.40, 95% CI: 0.24-0.67, p < 0.001). The most frequent genetic alteration was BRAFV600E mutation, found in 56.3% of PTMC submitted to DNA sequencing. No association between clinical, biological or histological characteristics of PTMC and BRAFV600E mutation was observed.

Conclusions: Thyroid autoimmunity and higher preoperative serum TSH level were independent predictors of PTMC incidentally discovered during thyroid surgery. Larger prospective studies are needed to better identify possible risk factors for papillary thyroid carcinoma initiation and progression.

目的:确定因假定良性疾病而接受甲状腺切除术的患者偶然发现甲状腺乳头状微癌(PTMC)的临床、生物学和病理学风险因素:横断面单中心研究,涉及2001-2019年间接受甲状腺手术的所有连续患者(N = 3015)。对所有医疗档案进行了回顾性审查。共分析了1961例良性组患者和145例PTMC组患者:良性组与PTMC组在年龄、性别、体重指数、吸烟状况、甲状腺体积或重量以及术前甲状腺素治疗方面无明显差异。在单变量分析中,循环抗甲状腺抗体、组织学甲状腺炎和血清促甲状腺激素(TSH)与PTMC显著相关。通过多变量分析,可能(OR:1.51,95% CI:0.99-2.28)和确定(OR:1.74,95% CI:1.09-2.78)的甲状腺自身免疫(P = 0.002)和较高的血清促甲状腺激素(OR:1.25,95% CI:1.08-1.45,p = 0.03),而甲状腺叶切除术与较低的PTMC风险相关(OR:0.40,95% CI:0.24-0.67,p V600E突变,在56.3%接受DNA测序的PTMC中发现。PTMC的临床、生物学或组织学特征与BRAFV600E突变之间没有关联:结论:甲状腺自身免疫和术前较高的血清促甲状腺激素水平是甲状腺手术中意外发现PTMC的独立预测因素。需要进行更大规模的前瞻性研究,以更好地确定甲状腺乳头状癌发生和发展的可能风险因素。
{"title":"Thyrotropin (TSH) and thyroid autoimmunity are predictive factors for the incidental discovery of papillary thyroid microcarcinoma during thyroidectomy.","authors":"Aglaia Kyrilli, Rafaella Schoinochoriti, Valerie Chatzopoulos, Nabila Bahar, Jason Bouziotis, Nicky D'Haene, Isabelle Salmon, Maria Ruiz, Bernard Corvilain","doi":"10.1007/s12020-024-03907-z","DOIUrl":"10.1007/s12020-024-03907-z","url":null,"abstract":"<p><strong>Purpose: </strong>To identify clinical, biological and pathological risk factors for the incidental discovery of papillary thyroid microcarcinomas (PTMCs) in patients undergoing thyroidectomy for presumed benign conditions.</p><p><strong>Methods: </strong>Cross sectional, single center study, involving all consecutive patients (N = 3015) who were submitted to thyroid surgery between 2001-2019. All medical files were retrospectively reviewed. A total of 1961 patients in the benign group and 145 patients in PTMC group were analyzed.</p><p><strong>Results: </strong>No significant differences in age, sex, body mass index, smoking status, thyroid volume or weight and preoperative thyroxine treatment between benign and PTMC groups were observed. Circulating anti- thyroid antibodies, histological thyroiditis and serum thyrotropin (TSH) were significantly associated with PTMC in univariable analysis. Independent risk factors for incidental PTMC by multivariable analysis where possible (OR: 1.51, 95% CI: 0.99-2.28) and certain (OR: 1.74, 95% CI: 1.09-2.78) thyroid autoimmunity (p = 0.002) and higher serum TSH (OR: 1.25, 95% CI: 1.08-1.45, p = 0.03), whereas thyroid lobectomy was associated with a lower risk of PTMC (OR: 0.40, 95% CI: 0.24-0.67, p < 0.001). The most frequent genetic alteration was BRAF<sup>V600E</sup> mutation, found in 56.3% of PTMC submitted to DNA sequencing. No association between clinical, biological or histological characteristics of PTMC and BRAF<sup>V600E</sup> mutation was observed.</p><p><strong>Conclusions: </strong>Thyroid autoimmunity and higher preoperative serum TSH level were independent predictors of PTMC incidentally discovered during thyroid surgery. Larger prospective studies are needed to better identify possible risk factors for papillary thyroid carcinoma initiation and progression.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"723-731"},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Lobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center. 分化型甲状腺癌患者的甲状腺叶切除术:智利一家三级中心的经验。
IF 3.7 3区 医学 Q2 Medicine Pub Date : 2024-11-01 Epub Date: 2024-06-14 DOI: 10.1007/s12020-024-03905-1
Ignacio Fuentes, Roberto Santana, Martin Espinoza, Eugenio Arteaga, Thomas Uslar, Rene Baudrand, Gilberto González, Francisco J Guarda, Nicole Lustig, Lorena Mosso, Flavia Nilo, Felipe Valenzuela, Francisco Domínguez, Hernán Eugenio González, Pablo H Montero, Francisco Cruz, Antonieta Solar, José M Domínguez

Purpose: Thyroid lobectomy (TL) is an appropriate treatment for up to 4 cm intrathyroidal differentiated thyroid cancer (DTC). There is scarce data regarding TL outside first-world centers. Our aim is to report a cohort of patients with DTC treated with TL in Chile.

Methods: We included DTC patients treated with TL, followed for at least 6 months, characterized their clinicopathological features and classified their risk of recurrence and response to treatment.

Results: Eighty-two patients followed for a median of 2.3 years (0.5-7.0). Seventy-three (89%) patients had papillary, 8 (9.8%) follicular and 1 (1.2%) high-grade DTC. The risk of recurrence was low in 56 (68.3%) and intermediate in 26 (31.7%). Eight (9.8%) patients required early completion thyroidectomy and radioiodine. At last follow-up, 52 (70.3%) had excellent, 19 (25.7%) had indeterminate, and 1 (1.4%) had structural incomplete response.

Conclusion: In a developing country, TL is an adequate option for appropriately selected DTC patients.

目的:甲状腺腺叶切除术(TL)是治疗长达 4 厘米的甲状腺内分化型甲状腺癌(DTC)的适当方法。在第一世界中心以外的地区,有关甲状腺叶切除术的数据很少。我们的目的是报告在智利接受TL治疗的DTC患者队列:我们纳入了接受TL治疗的DTC患者,对他们进行了至少6个月的随访,总结了他们的临床病理特征,并对他们的复发风险和治疗反应进行了分类:82名患者的随访时间中位数为2.3年(0.5-7.0年)。73例(89%)患者为乳头状DTC,8例(9.8%)为滤泡状DTC,1例(1.2%)为高级别DTC。56名(68.3%)患者的复发风险较低,26名(31.7%)患者的复发风险处于中等水平。8名(9.8%)患者需要尽早完成甲状腺切除术和放射性碘治疗。在最后一次随访中,52 例(70.3%)反应良好,19 例(25.7%)反应不确定,1 例(1.4%)反应不完全:结论:在发展中国家,对于经过适当选择的 DTC 患者来说,TL 是一种适当的选择。
{"title":"Lobectomy in patients with differentiated thyroid cancer: experience of a Chilean tertiary center.","authors":"Ignacio Fuentes, Roberto Santana, Martin Espinoza, Eugenio Arteaga, Thomas Uslar, Rene Baudrand, Gilberto González, Francisco J Guarda, Nicole Lustig, Lorena Mosso, Flavia Nilo, Felipe Valenzuela, Francisco Domínguez, Hernán Eugenio González, Pablo H Montero, Francisco Cruz, Antonieta Solar, José M Domínguez","doi":"10.1007/s12020-024-03905-1","DOIUrl":"10.1007/s12020-024-03905-1","url":null,"abstract":"<p><strong>Purpose: </strong>Thyroid lobectomy (TL) is an appropriate treatment for up to 4 cm intrathyroidal differentiated thyroid cancer (DTC). There is scarce data regarding TL outside first-world centers. Our aim is to report a cohort of patients with DTC treated with TL in Chile.</p><p><strong>Methods: </strong>We included DTC patients treated with TL, followed for at least 6 months, characterized their clinicopathological features and classified their risk of recurrence and response to treatment.</p><p><strong>Results: </strong>Eighty-two patients followed for a median of 2.3 years (0.5-7.0). Seventy-three (89%) patients had papillary, 8 (9.8%) follicular and 1 (1.2%) high-grade DTC. The risk of recurrence was low in 56 (68.3%) and intermediate in 26 (31.7%). Eight (9.8%) patients required early completion thyroidectomy and radioiodine. At last follow-up, 52 (70.3%) had excellent, 19 (25.7%) had indeterminate, and 1 (1.4%) had structural incomplete response.</p><p><strong>Conclusion: </strong>In a developing country, TL is an adequate option for appropriately selected DTC patients.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"692-698"},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141317168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Predicting the onset of overweight in Chinese high school students: a machine-learning approach in a one-year prospective cohort study. 预测中国高中生超重的发生:一年前瞻性队列研究中的机器学习方法。
IF 3.7 3区 医学 Q2 Medicine Pub Date : 2024-11-01 Epub Date: 2024-06-10 DOI: 10.1007/s12020-024-03902-4
Zikang Zhang, Wei Peng, Shaoming Sun, Jianguo Ma, Yining Sun, Fangwen Zhang

Objective: This study aimed to develop and evaluate machine-learning models for predicting the onset of overweight in adolescents aged 14‒17, utilizing easily collectible personal information.

Methods: This study was a one-year prospective cohort study. Baseline data were collected through anthropometric measurements and questionnaires, and the incidence of overweight was calculated one year later via anthropometric measurements. Predictive factors were selected through univariate analysis. Six machine-learning models were developed for predicting the onset of overweight. The SHapley Additive exPlanations (SHAP) was used for global and local interpretation of the models.

Results: Out of 1,241 adolescents, 204 (16.4%) were identified as overweight after one year. Nineteen features were associated with the overweight incidence in univariable analysis. Participants were randomly divided into a training group and a testing group in a 7:3 ratio. The Light Gradient Boosting Machine (LGBM) algorithm achieved outperformed other models, achieving the following metrics: Accuracy (0.956), Recall (0.812), Specificity (0.983), F1-score (0.855), AUC (0.961). Importance ranking revealed that the top 11 minimal feature set can maintain the stability of model performance.

Conclusions: The onset of overweight in adolescents was accurately predicted using easily collectible personal information. The LGBM-based model exhibited superior performance. Oversampling technique notably improved model performance. The model interpretation technique provided innovative strategies for managing adolescent overweight/obesity.

研究目的本研究旨在利用易于收集的个人信息,开发和评估用于预测 14-17 岁青少年开始超重的机器学习模型:本研究是一项为期一年的前瞻性队列研究。方法:本研究是一项为期一年的前瞻性队列研究,通过人体测量和问卷调查收集基线数据,一年后通过人体测量计算超重发生率。通过单变量分析选出了预测因素。开发了六个机器学习模型来预测超重的发生。结果:在 1241 名青少年中,有 204 人(16.4%)在一年后被确定为超重。在单变量分析中,有 19 个特征与超重发生率相关。参与者按 7:3 的比例随机分为训练组和测试组。轻梯度提升机(LGBM)算法的表现优于其他模型,达到了以下指标:准确率 (0.956)、召回率 (0.812)、特异性 (0.983)、F1-分数 (0.855)、AUC (0.961)。重要度排序显示,前 11 个最小特征集可以保持模型性能的稳定性:结论:利用易于收集的个人信息可以准确预测青少年超重的发生。基于 LGBM 的模型表现出卓越的性能。过度取样技术显著提高了模型性能。模型解释技术为管理青少年超重/肥胖症提供了创新策略。
{"title":"Predicting the onset of overweight in Chinese high school students: a machine-learning approach in a one-year prospective cohort study.","authors":"Zikang Zhang, Wei Peng, Shaoming Sun, Jianguo Ma, Yining Sun, Fangwen Zhang","doi":"10.1007/s12020-024-03902-4","DOIUrl":"10.1007/s12020-024-03902-4","url":null,"abstract":"<p><strong>Objective: </strong>This study aimed to develop and evaluate machine-learning models for predicting the onset of overweight in adolescents aged 14‒17, utilizing easily collectible personal information.</p><p><strong>Methods: </strong>This study was a one-year prospective cohort study. Baseline data were collected through anthropometric measurements and questionnaires, and the incidence of overweight was calculated one year later via anthropometric measurements. Predictive factors were selected through univariate analysis. Six machine-learning models were developed for predicting the onset of overweight. The SHapley Additive exPlanations (SHAP) was used for global and local interpretation of the models.</p><p><strong>Results: </strong>Out of 1,241 adolescents, 204 (16.4%) were identified as overweight after one year. Nineteen features were associated with the overweight incidence in univariable analysis. Participants were randomly divided into a training group and a testing group in a 7:3 ratio. The Light Gradient Boosting Machine (LGBM) algorithm achieved outperformed other models, achieving the following metrics: Accuracy (0.956), Recall (0.812), Specificity (0.983), F1-score (0.855), AUC (0.961). Importance ranking revealed that the top 11 minimal feature set can maintain the stability of model performance.</p><p><strong>Conclusions: </strong>The onset of overweight in adolescents was accurately predicted using easily collectible personal information. The LGBM-based model exhibited superior performance. Oversampling technique notably improved model performance. The model interpretation technique provided innovative strategies for managing adolescent overweight/obesity.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"600-611"},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141295766","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
C-Peptide and BMi predict anti-hyperglycemic treatment lines in breast cancer patients treated with Alpelisib. C肽和BMi可预测接受Alpelisib治疗的乳腺癌患者的抗高血糖治疗方案。
IF 3.7 3区 医学 Q2 Medicine Pub Date : 2024-11-01 Epub Date: 2024-07-04 DOI: 10.1007/s12020-024-03924-y
Elena Carrillo-Lopez, Fernando Sebastian-Valles, Carolina Sager La Ganga, Anabel Ballesteros, Victor Navas-Moreno, Dulce Bañón, María Pilar López Martí, Mónica Marazuela, José Alfonso Arranz Martín

Purpose: Alpelisib is a PI3K (Phosphoinositide 3-kinases) inhibitor used for breast cancer which develops hyperglycemia based on its action on glucose metabolism regulation. This study aims to identify potential risk factors predicting hyperglycemia development and the need for multiple treatments for hyperglycemia in patients receiving Alpelisib.

Methods: Fourteen women diagnosed with metastatic hormone receptor-positive breast cancer carrying PI3K mutations who initiated treatment with Alpelisib were monitored through consultations in the Oncology and Endocrinology departments. Non-parametric ROC curves were generated to assess the need for three or more antidiabetic medications to achieve glycemic control.

Results: The study population had a median age of 64 years (range:48-69) with a median body mass index (BMI) of 26.6 kg/m2 (range: 22.9-29.4). Overweight was observed in 35.7% of the participants and obesity in 21.4%. Fifty percent of the participants had prediabetes, and 85.7% developed hyperglycemia requiring pharmacological treatment, although none of them needed to discontinue treatment for this reason. Baseline C-peptide levels and BMI were associated with the number of antidiabetic drugs used (Spearman's Rho 0.553, p = 0.040; Spearman's Rho 0.581, p = 0.030, respectively). ROC curve analysis showed and area under the curve (AUC) of 0.819 for the variable risk profile (defined as baseline C-peptide >10.5 ng/ml and BMI > 27 kg/m2), whereas AUC values were 0.556 and 0.514 for HbA1c and baseline glucose, respectively, (p = 0.012).

Conclusion: A joint follow-up by an Oncology department and a Diabetes Unit can prevent treatment discontinuation in patients under Alpelisib therapy. Baseline BMI and plasma C-peptide levels can predict an increased need for anti-hyperglycemic treatment.

目的:Alpelisib是一种用于治疗乳腺癌的PI3K(磷脂酰肌醇3-激酶)抑制剂,由于其对葡萄糖代谢的调节作用,会导致高血糖。本研究旨在确定预测高血糖发生的潜在风险因素,以及接受 Alpelisib 治疗的患者是否需要对高血糖进行多种治疗:方法:通过肿瘤科和内分泌科的会诊,对14名确诊为携带PI3K突变的转移性激素受体阳性乳腺癌并开始接受Alpelisib治疗的女性患者进行监测。研究人员绘制了非参数 ROC 曲线,以评估是否需要使用三种或三种以上的抗糖尿病药物才能达到血糖控制:研究对象的中位年龄为 64 岁(范围:48-69),中位体重指数(BMI)为 26.6 kg/m2(范围:22.9-29.4)。35.7%的参与者超重,21.4%的参与者肥胖。50%的参与者患有糖尿病前期,85.7%的参与者出现了需要药物治疗的高血糖,但没有人因此而停止治疗。基线 C 肽水平和体重指数与使用的抗糖尿病药物数量相关(分别为 Spearman's Rho 0.553,p = 0.040;Spearman's Rho 0.581,p = 0.030)。ROC曲线分析显示,可变风险曲线(定义为基线C肽>10.5纳克/毫升和体重指数>27千克/平方米)的曲线下面积(AUC)为0.819,而HbA1c和基线血糖的AUC值分别为0.556和0.514(p = 0.012):结论:肿瘤科和糖尿病科联合随访可防止接受阿来替尼治疗的患者中断治疗。基线体重指数和血浆C肽水平可预测抗高血糖治疗需求的增加。
{"title":"C-Peptide and BMi predict anti-hyperglycemic treatment lines in breast cancer patients treated with Alpelisib.","authors":"Elena Carrillo-Lopez, Fernando Sebastian-Valles, Carolina Sager La Ganga, Anabel Ballesteros, Victor Navas-Moreno, Dulce Bañón, María Pilar López Martí, Mónica Marazuela, José Alfonso Arranz Martín","doi":"10.1007/s12020-024-03924-y","DOIUrl":"10.1007/s12020-024-03924-y","url":null,"abstract":"<p><strong>Purpose: </strong>Alpelisib is a PI3K (Phosphoinositide 3-kinases) inhibitor used for breast cancer which develops hyperglycemia based on its action on glucose metabolism regulation. This study aims to identify potential risk factors predicting hyperglycemia development and the need for multiple treatments for hyperglycemia in patients receiving Alpelisib.</p><p><strong>Methods: </strong>Fourteen women diagnosed with metastatic hormone receptor-positive breast cancer carrying PI3K mutations who initiated treatment with Alpelisib were monitored through consultations in the Oncology and Endocrinology departments. Non-parametric ROC curves were generated to assess the need for three or more antidiabetic medications to achieve glycemic control.</p><p><strong>Results: </strong>The study population had a median age of 64 years (range:48-69) with a median body mass index (BMI) of 26.6 kg/m<sup>2</sup> (range: 22.9-29.4). Overweight was observed in 35.7% of the participants and obesity in 21.4%. Fifty percent of the participants had prediabetes, and 85.7% developed hyperglycemia requiring pharmacological treatment, although none of them needed to discontinue treatment for this reason. Baseline C-peptide levels and BMI were associated with the number of antidiabetic drugs used (Spearman's Rho 0.553, p = 0.040; Spearman's Rho 0.581, p = 0.030, respectively). ROC curve analysis showed and area under the curve (AUC) of 0.819 for the variable risk profile (defined as baseline C-peptide >10.5 ng/ml and BMI > 27 kg/m<sup>2</sup>), whereas AUC values were 0.556 and 0.514 for HbA1c and baseline glucose, respectively, (p = 0.012).</p><p><strong>Conclusion: </strong>A joint follow-up by an Oncology department and a Diabetes Unit can prevent treatment discontinuation in patients under Alpelisib therapy. Baseline BMI and plasma C-peptide levels can predict an increased need for anti-hyperglycemic treatment.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"470-477"},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11489167/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141497454","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A novel nomogram to predict glucocorticoid response in thyroid-associated ophthalmopathy: findings from a pilot study. 预测甲状腺相关眼病患者糖皮质激素反应的新型提名图:一项试点研究的发现。
IF 3.7 3区 医学 Q2 Medicine Pub Date : 2024-11-01 Epub Date: 2024-07-05 DOI: 10.1007/s12020-024-03943-9
Junxin Ma, Zhenhua Leng, Daocheng Zuo, Xinyue Zhang, Chuanlin Zhang, Huanhuan Chen, Hu Liu

Purpose: Aimed to create a nomogram using clinical and eye-specific metrics to predict the efficacy of intravenous glucocorticoid (IVGC) therapy in patients with active and moderate-to-severe Thyroid-Associated Ophthalmopathy (TAO).

Methods: This study was conducted on 84 eyes from 42 moderate-to-severe TAO patients who received systemic IVGC therapy, and 42 eyes from 21 controls. Data were collected retrospectively from June 2020 to December 2021. The least absolute shrinkage and selection operator (LASSO) method was used to identify predictive factors for "unresponsiveness" to IVGC therapy. These factors were then analyzed using logistic regression to create a nomogram. The model's discriminative ability was robustly assessed using a Bootstrap resampling method with 1000 iterations for receiver operating characteristic (ROC) curve analysis.

Results: The LASSO analysis identified six factors with non-zero coefficients as significant, including Schirmer I test values, Meibomian gland (MG) diameter, MG length, disease duration, whole capillary vessel density (VD) in the radial peripapillary capillary (RPC), and whole macular VD for the superficial retinal capillary plexus (SRCP). The subsequent logistic regression model highlighted MG length, whole macular VD for SRCP, and disease duration as independent predictors of IVGC therapy response. The constructed nomogram demonstrated an area under the curve (AUC) of 0.82 (95% CI: 0.73-0.91), affirming the model's consistent and reliable ability to distinguish between responsive and non-responsive TAO patients.

Conclusion: Our nomogram, combining MG length (<4.875 mm), SRCP VD (<50.25%), and disease duration (>5.5 months), reliably predicts lower IVGC therapy effectiveness in active, moderate-to-severe TAO patients.

目的:旨在利用临床和眼部特异性指标创建一个提名图,以预测活动性中重度甲状腺相关眼病(TAO)患者静脉注射糖皮质激素(IVGC)治疗的疗效:这项研究的对象是42名接受全身IVGC治疗的中重度TAO患者的84只眼睛,以及21名对照组患者的42只眼睛。数据收集时间为 2020 年 6 月至 2021 年 12 月。采用最小绝对收缩和选择算子(LASSO)方法确定对IVGC疗法 "无反应 "的预测因素。然后使用逻辑回归对这些因素进行分析,以创建一个提名图。使用 Bootstrap 重采样法进行接收器操作特征曲线(ROC)分析,迭代 1000 次,对模型的判别能力进行稳健评估:LASSO分析确定了六个系数不为零的重要因素,包括Schirmer I测试值、睑板腺(MG)直径、睑板腺长度、病程、径向毛细血管周围毛细血管(RPC)的整个毛细血管密度(VD)和视网膜浅层毛细血管丛(SRCP)的整个黄斑VD。随后的逻辑回归模型强调了MG长度、SRCP的整个黄斑VD和病程是IVGC治疗反应的独立预测因素。所构建的提名图的曲线下面积(AUC)为 0.82(95% CI:0.73-0.91),证实了该模型在区分有反应和无反应的 TAO 患者方面具有一致而可靠的能力:结论:我们的提名图结合MG长度(5.5个月),能可靠地预测活跃的中重度TAO患者IVGC治疗的较低疗效。
{"title":"A novel nomogram to predict glucocorticoid response in thyroid-associated ophthalmopathy: findings from a pilot study.","authors":"Junxin Ma, Zhenhua Leng, Daocheng Zuo, Xinyue Zhang, Chuanlin Zhang, Huanhuan Chen, Hu Liu","doi":"10.1007/s12020-024-03943-9","DOIUrl":"10.1007/s12020-024-03943-9","url":null,"abstract":"<p><strong>Purpose: </strong>Aimed to create a nomogram using clinical and eye-specific metrics to predict the efficacy of intravenous glucocorticoid (IVGC) therapy in patients with active and moderate-to-severe Thyroid-Associated Ophthalmopathy (TAO).</p><p><strong>Methods: </strong>This study was conducted on 84 eyes from 42 moderate-to-severe TAO patients who received systemic IVGC therapy, and 42 eyes from 21 controls. Data were collected retrospectively from June 2020 to December 2021. The least absolute shrinkage and selection operator (LASSO) method was used to identify predictive factors for \"unresponsiveness\" to IVGC therapy. These factors were then analyzed using logistic regression to create a nomogram. The model's discriminative ability was robustly assessed using a Bootstrap resampling method with 1000 iterations for receiver operating characteristic (ROC) curve analysis.</p><p><strong>Results: </strong>The LASSO analysis identified six factors with non-zero coefficients as significant, including Schirmer I test values, Meibomian gland (MG) diameter, MG length, disease duration, whole capillary vessel density (VD) in the radial peripapillary capillary (RPC), and whole macular VD for the superficial retinal capillary plexus (SRCP). The subsequent logistic regression model highlighted MG length, whole macular VD for SRCP, and disease duration as independent predictors of IVGC therapy response. The constructed nomogram demonstrated an area under the curve (AUC) of 0.82 (95% CI: 0.73-0.91), affirming the model's consistent and reliable ability to distinguish between responsive and non-responsive TAO patients.</p><p><strong>Conclusion: </strong>Our nomogram, combining MG length (<4.875 mm), SRCP VD (<50.25%), and disease duration (>5.5 months), reliably predicts lower IVGC therapy effectiveness in active, moderate-to-severe TAO patients.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"824-833"},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141537728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subcutaneously transplanted xenogeneic protein recruits treg cells and M2 macrophages to induce browning of inguinal white adipose tissue. 皮下移植的异种蛋白会吸引 treg 细胞和 M2 巨噬细胞,诱导腹股沟白色脂肪组织褐变。
IF 3.7 3区 医学 Q2 Medicine Pub Date : 2024-11-01 Epub Date: 2024-06-20 DOI: 10.1007/s12020-024-03932-y
Shenglu Jiang, Lili Zhu, Yukun Xu, Zhao Liu, Jialin Cai, Tao Zhu, Qing Fan, Zhenxiong Zhao

Objective: To study whether subcutaneously embedding xenogeneic protein threads or synthetic polymer absorbable threads can improve obesity phenotypes and metabolic conditions, and to further explore its underlying mechanism.

Methods: Thirty-six 8-week-old ob/ob mice were randomly allocated to three groups, respectively, receiving catgut embedding, PGA thread embedding or sham treatment bilaterally to the groin. Individual parameters including weight, food intake, and core temperature are recorded and metabolism assessment, energy expenditure analysis, and PET/CT scanning are also performed at fixed timepoints. After surgical incision, the inguinal white adipose tissue was histologically examined and its expression profile was tested and compared among groups 4 weeks and 12 weeks after operation.

Results: Catgut embedding reduced weight gain and improved metabolic status in ob/ob mice. Browning of bilateral inguinal WAT (white adipose tissue) was induced after catgut embedding, with massive infiltration of Treg cells and M2 macrophages in the tissue slices of fat pads. IL-10 and TGF-β released by Treg cells targeted macrophages and the induced M2 macrophages increased the expression of thermogenic and anti-inflammatory genes in fat. The secretion of catecholamines by polarized M2 macrophages led to the activation of β3-AR-related pathways in adipocytes and the browning of adipose tissue.

Conclusions: Abdominal subcutaneous catgut embedding has the potential to combat obesity through the induction of WAT browning mediated by infiltrated Treg cells and macrophages.

目的研究皮下包埋异种蛋白线或合成高分子可吸收线能否改善肥胖表型和代谢状况,并进一步探讨其潜在机制:将36只8周大的肥胖/ob小鼠随机分为三组,分别在腹股沟双侧接受猫肠包埋、PGA线包埋或假治疗。在固定时间点记录体重、食物摄入量和核心温度等个体参数,并进行新陈代谢评估、能量消耗分析和 PET/CT 扫描。手术切口后,对腹股沟白色脂肪组织进行组织学检查,检测其表达谱,并在术后 4 周和 12 周进行组间比较:结果:猫肠包埋减少了肥胖/ob小鼠的体重增加,改善了代谢状况。包埋肠道后诱导双侧腹股沟 WAT(白色脂肪组织)褐变,脂肪垫组织切片中出现大量 Treg 细胞和 M2 巨噬细胞浸润。Treg细胞释放的IL-10和TGF-β靶向巨噬细胞,诱导的M2巨噬细胞增加了脂肪中致热和抗炎基因的表达。极化的 M2 巨噬细胞分泌儿茶酚胺,导致脂肪细胞中 β3-AR 相关通路的激活和脂肪组织的棕色化:结论:腹部皮下猫肠包埋具有通过浸润的 Treg 细胞和巨噬细胞介导的 WAT 褐变诱导来对抗肥胖的潜力。
{"title":"Subcutaneously transplanted xenogeneic protein recruits treg cells and M2 macrophages to induce browning of inguinal white adipose tissue.","authors":"Shenglu Jiang, Lili Zhu, Yukun Xu, Zhao Liu, Jialin Cai, Tao Zhu, Qing Fan, Zhenxiong Zhao","doi":"10.1007/s12020-024-03932-y","DOIUrl":"10.1007/s12020-024-03932-y","url":null,"abstract":"<p><strong>Objective: </strong>To study whether subcutaneously embedding xenogeneic protein threads or synthetic polymer absorbable threads can improve obesity phenotypes and metabolic conditions, and to further explore its underlying mechanism.</p><p><strong>Methods: </strong>Thirty-six 8-week-old ob/ob mice were randomly allocated to three groups, respectively, receiving catgut embedding, PGA thread embedding or sham treatment bilaterally to the groin. Individual parameters including weight, food intake, and core temperature are recorded and metabolism assessment, energy expenditure analysis, and PET/CT scanning are also performed at fixed timepoints. After surgical incision, the inguinal white adipose tissue was histologically examined and its expression profile was tested and compared among groups 4 weeks and 12 weeks after operation.</p><p><strong>Results: </strong>Catgut embedding reduced weight gain and improved metabolic status in ob/ob mice. Browning of bilateral inguinal WAT (white adipose tissue) was induced after catgut embedding, with massive infiltration of Treg cells and M2 macrophages in the tissue slices of fat pads. IL-10 and TGF-β released by Treg cells targeted macrophages and the induced M2 macrophages increased the expression of thermogenic and anti-inflammatory genes in fat. The secretion of catecholamines by polarized M2 macrophages led to the activation of β3-AR-related pathways in adipocytes and the browning of adipose tissue.</p><p><strong>Conclusions: </strong>Abdominal subcutaneous catgut embedding has the potential to combat obesity through the induction of WAT browning mediated by infiltrated Treg cells and macrophages.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"631-643"},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141426593","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma. 评估甲状腺乳头状癌患者BRAF和RAS突变预后影响的计算方法。
IF 3.7 3区 医学 Q2 Medicine Pub Date : 2024-11-01 Epub Date: 2024-06-17 DOI: 10.1007/s12020-024-03911-3
Tahereh Haghzad, Babak Khorsand, S Adeleh Razavi, Mehdi Hedayati

Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, posing a growing clinical challenge. PTC exhibits two age-related peaks, with established risk factors including family history and radiation exposure. Managing even low-risk, localized PTC cases remain complex, with growing interest in active surveillance as an alternative to immediate surgery. This study employed single-cell RNA sequencing (scRNA-Seq) to explore the predictive value of BRAF and RAS mutations in PTC, shedding light on their impact on disease progression and outcomes. The analyses emphasized the significance of BRAF and RAS mutations in tumor advancement, particularly the unique BRAF V600E mutation associated with aggressive features. The methodology involved scRNA-Seq analysis of PTC and normal samples, unveiling distinct cell clusters and indicating upregulated BRAF and RAS genes. Pathway enrichment analysis highlighted altered biological processes and immune-related pathways in PTC. The study consolidated previous research showing the prevalence of BRAF and RAS mutations in PTC, subtypes with distinct molecular profiles, and the impact of TERT promoter mutations on disease severity. In summary, this study unveils the complex interplay of genetic mutations and the cellular microenvironment in PTC through scRNA-Seq. The upregulated BRAF and RAS genes suggest their roles as PTC drivers, and pathway enrichment reveals alterations in immune-related processes. This synthesis of prior research enhances our understanding of PTC's molecular foundations, informing better prognosis and personalized treatment approaches. These insights advance the landscape of PTC management and provide directions for further research.

甲状腺乳头状癌(PTC)是最常见的甲状腺癌,其临床挑战日益严峻。PTC呈现两个与年龄相关的高峰,既定的风险因素包括家族史和辐射暴露。即使是低风险、局部性的PTC病例,治疗起来也很复杂,人们越来越关注积极监测,以替代立即手术。本研究采用单细胞 RNA 测序(scRNA-Seq)技术探讨了 PTC 中 BRAF 和 RAS 基因突变的预测价值,揭示了它们对疾病进展和预后的影响。分析强调了BRAF和RAS突变在肿瘤进展中的重要性,尤其是与侵袭性特征相关的独特BRAF V600E突变。分析方法包括对 PTC 和正常样本进行 scRNA-Seq 分析,揭示了不同的细胞群,并指出了上调的 BRAF 和 RAS 基因。通路富集分析强调了 PTC 中改变的生物过程和免疫相关通路。该研究巩固了之前的研究,这些研究显示了 BRAF 和 RAS 基因突变在 PTC 中的普遍性、具有不同分子特征的亚型以及 TERT 启动子突变对疾病严重性的影响。总之,这项研究通过scRNA-Seq揭示了PTC中基因突变与细胞微环境之间复杂的相互作用。BRAF和RAS基因的上调表明了它们作为PTC驱动因子的作用,而通路富集则揭示了免疫相关过程的改变。这项综合先前研究的成果增强了我们对 PTC 分子基础的了解,为更好的预后和个性化治疗方法提供了依据。这些见解推进了 PTC 的管理,并为进一步的研究提供了方向。
{"title":"A computational approach to assessing the prognostic implications of BRAF and RAS mutations in patients with papillary thyroid carcinoma.","authors":"Tahereh Haghzad, Babak Khorsand, S Adeleh Razavi, Mehdi Hedayati","doi":"10.1007/s12020-024-03911-3","DOIUrl":"10.1007/s12020-024-03911-3","url":null,"abstract":"<p><p>Papillary thyroid carcinoma (PTC) is the most common thyroid cancer, posing a growing clinical challenge. PTC exhibits two age-related peaks, with established risk factors including family history and radiation exposure. Managing even low-risk, localized PTC cases remain complex, with growing interest in active surveillance as an alternative to immediate surgery. This study employed single-cell RNA sequencing (scRNA-Seq) to explore the predictive value of BRAF and RAS mutations in PTC, shedding light on their impact on disease progression and outcomes. The analyses emphasized the significance of BRAF and RAS mutations in tumor advancement, particularly the unique BRAF V600E mutation associated with aggressive features. The methodology involved scRNA-Seq analysis of PTC and normal samples, unveiling distinct cell clusters and indicating upregulated BRAF and RAS genes. Pathway enrichment analysis highlighted altered biological processes and immune-related pathways in PTC. The study consolidated previous research showing the prevalence of BRAF and RAS mutations in PTC, subtypes with distinct molecular profiles, and the impact of TERT promoter mutations on disease severity. In summary, this study unveils the complex interplay of genetic mutations and the cellular microenvironment in PTC through scRNA-Seq. The upregulated BRAF and RAS genes suggest their roles as PTC drivers, and pathway enrichment reveals alterations in immune-related processes. This synthesis of prior research enhances our understanding of PTC's molecular foundations, informing better prognosis and personalized treatment approaches. These insights advance the landscape of PTC management and provide directions for further research.</p>","PeriodicalId":11572,"journal":{"name":"Endocrine","volume":" ","pages":"707-722"},"PeriodicalIF":3.7,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141418396","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Endocrine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1